Compositions and methods for the treatment of motion sickness and emesis
The present disclosure comprises compositions and methods for the treatment, including one or more of prevention and rescue therapy, of subjects at risk for or suffering from motion sickness, which may include nausea or vomiting/emesis associated with motion. In particular, compositions and methods for nasal administration of scopolamine are provided.
1 . An intranasal pharmaceutical composition for use in a human subject comprising a therapeutically effective amount of scopolamine or a pharmaceutically acceptable salt thereof, wherein the intranasal pharmaceutical composition is capable of the prevention of or rescue from one or more symptoms related to motion in a human subject, and wherein the composition has a viscosity of about 1750 to about 3500 centistokes.
2 . The intranasal pharmaceutical composition of claim 1 , wherein when the composition is administered to a subject, the composition is capable of exhibiting an AUC for unbound scopolamine or a pharmaceutically acceptable salt thereof that is approximately 40% of the unbound scopolamine or a pharmaceutically acceptable salt thereof for transdermal administration and wherein the composition is capable of an approximately equivalent Cmax for unbound scopolamine or a pharmaceutically acceptable salt thereof as compared to transdermal administration of scopolamine or a pharmaceutically acceptable salt thereof.
3 . The intranasal pharmaceutical composition of claim 1 , wherein the therapeutically effective amount comprises from about 0.15 to about 0.25 mg scopolamine or a pharmaceutically acceptable salt thereof.
4 . The intranasal pharmaceutical composition of claim 3 , wherein the composition comprises 0.2 mg scopolamine.
5 . The intranasal pharmaceutical composition of claim 1 , wherein the composition has a viscosity of about 2100 to 2700 centistokes.
6 . The intranasal pharma composition of claim 1 , wherein the composition comprises at least one buffer, gelling agent, antioxidant and humectant, and combinations thereof.
7 . The intranasal pharmaceutical composition of claim 6 , wherein the composition comprises at least one of citric acid, polyvinyl alcohol, benzalkonium chloride, sodium metabisulfite, sodium citrate dihydrate and glycerin, and combinations thereof.
8 . The intranasal composition of claim 7 , wherein:
a) the citric acid is present at a concentration of from about 0.7% (w/w) to about 0.8% (w/w);
b) the polyvinyl alcohol is present at a concentration of from about 8% (w/w) to about 12% (w/w);
c) the benzalkonium chloride is a solution of 50% benzalkonium chloride at a concentration of from about 0.03% (w/w) to about 0.05% (w/w);
d) the sodium metabisulfite is present at a concentration of from about 0.05% (w/w) to about 0.15% (w/w); and
e) glycerin is present at a concentration of from about 3% (w/w) to about 7% (w/w).
9 . The intranasal composition of claim 6 , wherein the composition has a pH of from about 3.2 to about 3.6.
10 . The intranasal pharmaceutical composition of claim 1 , wherein the composition is capable of providing absolute bioavailability of about 10-14% when administered to a subject.
11 . An intranasal pharmaceutical composition for use in a human subject comprising a therapeutically effective amount of scopolamine or a pharmaceutically acceptable salt thereof at a concentration of from about 0.15% (w/w) to about 0.18% (w/w), wherein the composition is capable of prevention of, or rescue from, one or more of nausea or vomiting related to motion in a human subject, wherein when the composition is administered to a subject, the composition is capable of exhibiting an AUC for unbound scopolamine or a pharmaceutically acceptable salt thereof that is approximately 40% lower than unbound scopolamine or a pharmaceutically acceptable salt thereof for transdermal administration, wherein the composition is capable of an approximately equivalent Cmax for unbound scopolamine or a pharmaceutically acceptable salt thereof as compared to transdermal administration of scopolamine or a pharmaceutically acceptable salt thereof, and wherein the composition has a viscosity of at about 1750 to about 3500 centistokes.
12 . The intranasal pharmaceutical composition of claim 11 , wherein the composition is a gel having a viscosity of about 2000 to about 3000 centistokes.
13 . The intranasal pharmaceutical composition of claim 12 , wherein the composition has a viscosity of about 2100 to 2700 centistokes.
14 . The intranasal pharmaceutical composition of claim 11 , wherein the therapeutically effective amount comprises from about 0.15 to about 0.25 mg scopolamine or a pharmaceutically acceptable salt thereof.
15 . The intranasal pharmaceutical composition of claim 14 , wherein the composition comprises 0.2 mg scopolamine.
16 . The intranasal pharmaceutical composition of claim 11 , wherein the composition further comprises at least one buffer, gelling agent, antioxidant and humectant, and combinations thereof.
17 . The intranasal composition of claim 16 , wherein the composition comprises at least one of citric acid, polyvinyl alcohol, benzalkonium chloride, sodium metabisulfite, sodium citrate dihydrate and glycerin, and combinations thereof.
18 . The intranasal composition of claim 17 , wherein:
a) the citric acid is present at a concentration of from about 0.7% (w/w) to about 0.8% (w/w);
b) the polyvinyl alcohol is present at a concentration of from about 8% (w/w) to about 12% (w/w);
c) the benzalkonium chloride is a solution of 50% benzalkonium chloride at a concentration of from about 0.03% (w/w) to about 0.05% (w/w);
d) the sodium metabisulfite is present at a concentration of from about 0.05% (w/w) to about 0.15% (w/w); and
e) glycerin is present at a concentration of from about 3% (w/w) to about 7% (w/w).
19 . The intranasal composition of claim 16 , wherein the composition has a pH of from about 3.2 to about 3.6.
20 . The intranasal pharmaceutical composition of claim 11 , wherein the composition is capable of providing absolute bioavailability of about 10-14% when administered to a subject.
21 . The intranasal pharmaceutical composition of claim 1 or 11 , wherein the composition has a viscosity of about 1750 to about 2600 centistokes.
22 . The intranasal pharmaceutical composition of claim 21 , wherein the composition has a viscosity of about 1800 to 2600 centistokes.
23 . The intranasal pharmaceutical composition of claim 21 , wherein the composition has a viscosity of about 2000 to 2600 centistokes.
24 . The intranasal pharmaceutical composition of claim 21 , wherein the composition has a viscosity of about 2300 centistokes.